Fox Business - The Power to Prosper
Search Site


CBS misses 2Q estimates for revenue

Claman on Call: FBN’s Liz Claman with an after-hours web exclusive on the markets, CBS, News Corp., Zynga and Harman International earnings.

Read More

  1. Teva 1Q Profit Up 13% On Branded, Generic Drug Sales

    Teva Pharmaceutical Industries Ltd. (TEVA) said Wednesday its first-quarter profit rose 13%, as sales growth for branded and generic drugs in the U.S. and emerging m...

  2. Mylan Seeks To Overturn FDA's Provigil Decision

    DOW JONES NEWSWIRESMylan Inc. (MYL) said it is seeking to overturn a decision by the U.S. Food and Drug Administration that awarded Teva Pharmaceutical Industries Lt...

  3. Myriad Genetics Enters Testing Agreement With Teva Subsidiary

    DOW JONES NEWSWIRESMolecular-diagnostic company Myriad Genetics Inc. (MYGN) said Wednesday it agreed to conduct BRCA1 and BRCA2 mutation testing for Cephalon Inc., a...

  4. Teva 4Q Net Drops 34% On Acquisition Costs; Sales Up 28%

    Teva Pharmaceutical Industries Ltd.'s (TEVA) fourth-quarter profit declined 34%, as higher acquisition-related costs more than offset a revenue increase fueled by la...

  5. Teva Recalls 1 Batch Of Treanda Due To Presence Of Glass In Vial

    Teva Pharmaceutical Industries Ltd.'s (TEVA) Cephalon unit has recalled one batch of its Treanda cancer drug after the discovery of glass fragments in a single vial....

  6. Is Your Doctor on Big Pharma's Payroll?

    Medical device and pharmaceutical companies are gearing up for a big change in the way they deal with their most important middlemen: doctors. Beginning in 2013, the...

  7. Stocks Close Lower in Choppy Trading

    FOX Business: The Power to ProsperThe markets ended a volatile trading session slightly lower as traders weighed the market impact of the death of terror mastermind ...

  8. Teva Announces Plans to Buy Cephalon for $6.8B

    FBN's Robert Gray breaks down mid-morning market news.

  9. Global Markets Up on News of Bin Laden's Death

    FBN's Connell McShane breaks down the stories moving the markets around the world.

  10. Teva Beats Out Valeant in $6.8B Cephalon Bid

    Topping a bid by rival Valeant (NYSE:VRX), Teva Pharmaceutical (NASDAQ:TEVA) has inked a deal to acquire Cephalon (NASDAQ:CEPH) for $6.8 billion in an effort to buil...

  11. Teva to acquire Cephalon , topping Valeant

    NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA> <TEVA.O> plans to acquire specialty drugmaker Cephalon <CEPH.O> for $81.50 a share, topping an unso...

  12. Gov't Spends $6M to Study How Squid Use Camouflage

    Citizens Against Government Waste's Tom Schatz argues the government is wasting money on research such as this rather on necessary defense spending.

  1. Tech stocks lag, utilities hit all-time highs

    FBN’s Nicole Petallides breaks down the day in the markets.

  2. U.S. Seeks $1B from Drug Firms Delaying Generics

    The U.S. Federal Trade Commission seeks a settlement of $1 billion or more from pharmaceutical companies it has sued for delaying the sale of cheaper medicines after...

  3. Some Drug Makers Cut Payments, Meals Provided to Doctors

    Two pharmaceutical companies that are among the biggest payers of fees to doctors reduced such spending last year by double-digit percentages, as greater transparenc...

  4. Top Court to Decide on Deals to Delay Cheaper Drugs

    The U.S. Supreme Court will hear arguments on Monday over whether big drug companies can settle patent litigation with generic rivals by making deals to keep cheaper...

  5. Teva CEO Vows Cost Cuts, Deals, Divestitures in Reshaping Drug Maker

    Teva Pharmaceutical Industries Ltd.'s (TEVA) new leader vowed to reshape the drug maker, including a reduction in annual costs of up to $2 billion over the next five...

  6. Valeant to Buy Medicis in $2.6B Deal

    Valeant Pharmaceuticals International Inc agreed on Monday to buy Medicis Pharmaceutical Corp for $2.6 billion in cash, in a deal that will add Botox competitor Dysp...

  7. Don’t Fear Current Gas Spike?

    Richard Soultanian of NUS Consulting argues the current spike in gas prices will not last.

‹ Prev12Next ›
Freebase CC-BY
Source: Cephalon on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL